Personalis reported a significant 76% year-over-year revenue increase to $25.6 million, driven by a pivot toward clinical diagnostics and population sequencing. While top-line growth was strong, net loss widened to $33.8 million as operating expenses scaled.
Key Highlights
- Clinical test volume surged 200% to 13,157 tests, generating $4.4 million in clinical revenue compared to just $0.4 million in the prior-year period.
- Population sequencing revenue from the VA MVP project reached $4.0 million, up from $0.2 million last year.
- Selling, general, and administrative expenses doubled to $26.0 million, reflecting increased headcount and costs related to the pending Tempus AI merger.
- The company maintained a solid liquidity position with $190.6 million in cash and short-term investments to support operations through the acquisition close.